<DOC>
	<DOCNO>NCT01172821</DOCNO>
	<brief_summary>The aim trial evaluate efficacy safety 2.5 5 mcg tiotropium 24-week treatment period compare placebo salmeterol ( 50 mcg twice daily ) . Tiotropium inhalation solution deliver Respimat® inhaler examine top maintenance treatment inhale corticosteroid controller medication patient moderate persistent asthma . Efficacy safety assess measuring effect lung function , effect asthma exacerbation , effect quality life , effect asthma control , effect health care resource utilisation , number adverse event .</brief_summary>
	<brief_title>Evaluation Tiotropium 2.5 5 mcg Once Daily Delivered Via Respimat® Inhaler Compared Placebo Salmeterol HydroFluoroAlkane ( HFA ) Metered Dose Inhaler ( MDI ) ( 50 mcg Twice Daily ) Patient With Moderate Persistent Asthma II</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign date Informed Consent Form consistent International Conference Harmonisation Good Clinical Practice ( ICHGCP ) guideline local legislation prior participation trial ( i.e . prior trial procedure , include pretrial washout medication medication restriction pulmonary function test Visit 1 ) . 2 . Male female patient age least 18 year 75 year . 3 . All patient must least 3 month history asthma time enrolment trial . The diagnosis confirm Visit 1 fulfil inclusion criterion 5 . 4 . The initial diagnosis asthma must make patient 's age 40 . 5 . The diagnosis asthma confirm Visit 1 bronchodilator reversibility ( 15 minute 400 mcg salbutamol ( albuterol ) ) result Forced Expiratory Volume one second ( FEV1 ) increase least 12 % least 200mL . 6 . All patient must maintenance treatment medium , stable dose inhaled corticosteroid least 4 week prior Visit 1 . 7 . All patient must symptomatic Visit 1 ( screen ) prior randomisation Visit 2 define Asthma Control Questionnaire ( ACQ ) mean score least 1.5 . 8 . All patient must prebronchodilator FEV1 least 60 % less equal 90 % predict normal Visit 1 . 9 . Variation absolute FEV1 value Visit 1 ( prebronchodilator ) compare Visit 2 ( predose ) must within ± 30 % . 10 . Patients must neversmokers exsmokers stop smoke least one year prior enrolment ( Visit 0 ) smoke history le 10 pack year . 11 . Patients must able use Respimat® inhaler meter dose inhaler correctly . 12 . Patients must able perform trial related procedure include technically acceptable pulmonary function test use electronic diary/peak flow meter . Exclusion criterion : 1 . Patients significant disease asthma . A significant disease define disease , opinion investigator , may ( ) put patient risk participation trial , ( ii ) influence result trial , ( iii ) cause concern regard patient 's ability participate trial . 2 . Patients clinically relevant abnormal screening ( Visit 1 ) haematology blood chemistry abnormality define significant disease define exclusion criterion 1 . 3 . Patients recent history ( i.e . six month less ) myocardial infarction . 4 . Patients hospitalise cardiac failure past year . 5 . Patients unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year . 6 . Patients lung disease asthma ( e.g . Chronic Obstructive Pulmonary Disease ( COPD ) ) . 7 . Patients know active tuberculosis . 8 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . Patients treat basal cell carcinoma allow . 9 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion . 1 . 10 . Patients significant alcohol drug abuse within past two year . 11 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program 6 week prior Visit 1 ( screen ) . 12 . Patients know hypersensitivity anticholinergic drug , benzalkonium chloride ( BAC ) , ethylenediamineteraacetic acid ( EDTA ) , salmeterol xinafoate component study medication delivery system . 13 . Pregnant nursing woman . 14 . Women childbearing potential use highly effective method birth control . 15 . Patients take investigational drug within four week prior Visit 1 . 16 . Patients treat betablocker medication within four week prior Visit 1 and/or screen period . Topical cardioselective betablocker eye medication nonnarrow angle glaucoma allow . 17 . Patients treat longacting anticholinergic tiotropium ( Spiriva® ) within four week prior Visit 1 and/or screen period . 18 . Patients treat oral patch betaadrenergics within four week prior Visit 1 and/or Screening period . 19 . Patients treat oral corticosteroid within four week prior Visit 1 and/or screen period . 20 . Patients treat antiIgE antibody , e.g . omalizumab ( Xolair® ) , within 6 month prior Visit 1 and/or screen period . 21 . Patients treat cromone within two week prior Visit 1 and/or screen period . 22 . Patients treat methylxanthines phosphodiesterase 4 inhibitor within two week prior Visit 1 and/or screen period . 23 . Patients treat nonapproved accord international guideline recommend `` experimental '' drug routine asthma therapy within four week prior Visit 1 and/or screen period . 24 . Patients asthma exacerbation respiratory tract infection iin four week prior Visit 1 and/or screen period . 25 . Patients previously randomise trial respective twin trial ( 205.418 ) currently participate another trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>